throbber
Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 1 of 25 PageID #: 1
`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`
`
`
`
`
`
`C.A. No. ________________
`
`
`
`
`
`
`)))))))))))))
`
`
`
`BOEHRINGER INGELHEIM
`PHARMACEUTICALS INC., BOEHRINGER
`INGELHEIM INTERNATIONAL GMBH and
`BOEHRINGER INGELHEIM CORPORATION,
`
`
`Plaintiffs,
`
`
`v.
`
`
`LUPIN LTD. and
`LUPIN PHARMACEUTICALS, INC.,
`
`
`Defendants.
`
`COMPLAINT
`
`Plaintiffs, Boehringer
`
`Ingelheim Pharmaceuticals
`
`Inc.; Boehringer
`
`Ingelheim
`
`International GmbH; and Boehringer Ingelheim Corporation, by their undersigned attorneys, for
`
`their Complaint against Defendants, Lupin Ltd. and Lupin Pharmaceuticals, Inc., hereby allege
`
`as follows:
`
`NATURE OF THE ACTION
`
`
`
`This is an action for patent infringement arising under the Food and Drug Laws
`
`and Patent Laws of the United States, Titles 21 and 35 of the United States Code, respectively,
`
`arising from Defendants’ submission of an Abbreviated New Drug Application (“ANDA”) to the
`
`Food and Drug Administration (“FDA”) seeking approval to manufacture and sell generic
`
`versions of Plaintiffs’ TRIJARDY® XR
`
`(empagliflozin,
`
`linagliptin, and metformin
`
`hydrochloride extended release) tablets prior to the expiration of United States Patent Nos.
`
`8,551,957, 9,155,705, 9,415,016, 9,949,998, 10,022,379, 10,258,637, and 10,406,172.
`
`
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 2 of 25 PageID #: 2
`
`
`
`THE PARTIES
`
`
`
`Plaintiff Boehringer Ingelheim Pharmaceuticals Inc. (“BIPI”) is a corporation
`
`organized and existing under the laws of the State of Delaware, having a principal place of
`
`business at 900 Ridgebury Rd., Ridgefield, CT 06877.
`
`
`
`Plaintiff Boehringer Ingelheim International GmbH (“BII”) is a private limited
`
`liability company organized and existing under the laws of Germany, having a principal place of
`
`business at Binger Strasse 173, 55216 Ingelheim, Germany.
`
`
`
`Plaintiff Boehringer Ingelheim Corporation (“BIC”) is a corporation organized
`
`and existing under the laws of Nevada, having a principal place of business at 900 Ridgebury
`
`Road, Ridgefield, CT 06877.
`
`
`
`BIPI, BII, and BIC are collectively referred to hereinafter as “Boehringer” or
`
`“Plaintiffs.”
`
`
`
`On information and belief, Defendant Lupin Ltd. is a corporation organized and
`
`existing under the laws of India, having a principal place of business at Laxmi Towers, Bandra
`
`Kurla Complex, Bandra (East), Mumbai, India 400051.
`
`
`
`On information and belief, Lupin Ltd. controls and directs a wholly owned
`
`subsidiary in the United States named Lupin Pharmaceuticals, Inc. (“Lupin Pharma”). Lupin
`
`Pharma is a Delaware corporation having a principal place of business at 111 South Calvert
`
`Street, Baltimore, Maryland 21202.
`
`
`
`
`
`Lupin Ltd. and Lupin Pharma are collectively referred to hereinafter as “Lupin.”
`
`On information and belief, Lupin Ltd. is in the business of, among other things,
`
`developing, preparing, manufacturing, selling, marketing, and distributing generic drugs,
`
`including distributing, selling, and marketing generic drugs throughout the United States,
`
`including within the state of Delaware, through its own actions and through the actions of its
`
`2
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 3 of 25 PageID #: 3
`
`
`
`agents and subsidiaries, including Lupin Pharma, from which Lupin Ltd. derives a substantial
`
`portion of its revenue.
`
`
`
`On information and belief, Lupin Ltd. acted in concert with Lupin Pharma to
`
`prepare and submit ANDA No. 215072 (the “Lupin ANDA”) for Lupin’s 5 mg/2.5 mg/1000 mg;
`
`10 mg/5 mg/1000 mg; 12.5 mg/2.5 mg/1000 mg; 25 mg/5 mg/1000 mg
`
`empagliflozin/linagliptin/metformin extended-release tablets (the “Lupin ANDA Product”),
`
`which was done at the direction of, under the control of, and for the direct benefit of Lupin Ltd.
`
`Following FDA approval of the Lupin ANDA, Lupin Ltd. will manufacture and supply the
`
`approved generic product to Lupin Pharma, which will then market and sell the product
`
`throughout the United States at the direction, under the control, and for the direct benefit of
`
`Lupin Ltd.
`
`JURISDICTION AND VENUE
`
`
`
`This action arises under the patent laws of the United States, 35 U.S.C. §§ 100 et
`
`seq., generally, and 35 U.S.C. § 271(e)(2), specifically, and this Court has jurisdiction over the
`
`subject matter of this action under 28 U.S.C. §§ 1331 and 1338(a).
`
`
`
`Venue is proper in this Court because, among other things, Lupin Pharma is
`
`incorporated in the State of Delaware and therefore “resides” in this judicial district and/or has
`
`committed acts of infringement in this district and has a regular and established place of business
`
`in this district. 28 U.S.C. § 1400(b). Lupin Ltd. is a foreign corporation not residing in any
`
`United States district and may be sued in any judicial district. 28 U.S.C. § 1391(c). Moreover,
`
`Lupin has litigated previous Hatch-Waxman patent infringement disputes in the District of
`
`Delaware.
`
`
`
`
`
`3
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 4 of 25 PageID #: 4
`
`
`
`PERSONAL JURISDICTION OVER LUPIN LTD.
`
`Plaintiffs reallege paragraphs 1-12 as if fully set forth herein.
`
`On information and belief, Lupin Ltd. develops, manufactures, and/or distributes
`
`
`
`
`
`generic drugs for sale and use throughout the United States, including in this judicial district.
`
`
`
`This Court has personal jurisdiction over Lupin Ltd. because, inter alia, Lupin
`
`Ltd., on information and belief: (1) has substantial, continuous, and systematic contacts with this
`
`State, either directly or through at least one of its wholly-owned subsidiaries or agents;
`
`(2) intends to market, sell, and/or distribute Lupin Ltd. infringing ANDA Products to residents of
`
`this State upon approval of ANDA No. 215072, either directly or through at least one of its
`
`wholly-owned subsidiaries or agents; (3) enjoys substantial income from sales of its generic
`
`pharmaceutical products in this State on its own and through Lupin Pharma, which is a Delaware
`
`corporation; and (4) wholly owns Lupin Pharma, which is a Delaware corporation and is
`
`registered as a pharmacy wholesaler and controlled substances distributor/manufacturer with the
`
`Delaware Division of Professional Regulation.
`
`
`
`On information and belief, Lupin Ltd. has not contested jurisdiction in Delaware
`
`in one or more prior cases arising out of the filing of its ANDAs, and it has filed counterclaims in
`
`such cases. See, e.g., Boehringer Ingelheim Pharm. Inc. v. Lupin Ltd., C.A. No. 18-1690-CFC
`
`(D. Del.); Bial-Portela v. Lupin Ltd., C.A. No. 18-312-CFC (D. Del.); Boehringer Ingelheim
`
`Pharmaceuticals Inc. et al v. Lupin Limited et al, C.A. No. 19-01866-CFC (D. Del.).
`
`
`
`Alternatively, to the extent the above facts do not establish personal jurisdiction
`
`over Lupin Ltd., this Court may exercise jurisdiction over Lupin Ltd. pursuant to Fed. R. Civ. P.
`
`4(k)(2) because: (a) Plaintiffs’ claims arise under federal law; (b) Lupin Ltd. would be a foreign
`
`defendant not subject to personal jurisdiction in the courts of any State; and (c) Lupin Ltd. has
`
`sufficient contacts with the United States as a whole, including, but not limited to, filing ANDAs
`
`4
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 5 of 25 PageID #: 5
`
`
`
`with the FDA and manufacturing and selling generic pharmaceutical products that are distributed
`
`throughout the United States, such that this Court’s exercise of jurisdiction over Lupin Ltd.
`
`satisfies due process.
`
`PERSONAL JURISDICTION OVER LUPIN PHARMA
`
`Plaintiffs reallege paragraphs 1-17 as if fully set forth herein.
`
`On information and belief, Lupin Pharma develops, manufactures, and/or
`
`
`
`
`
`distributes generic drugs for sale and use throughout the United States, including in this judicial
`
`district.
`
`
`
`This Court has personal jurisdiction over Lupin Pharma because, inter alia, Lupin
`
`Pharma, on information and belief: (1) is incorporated under the laws of the State of Delaware;
`
`(2) is registered as a pharmacy wholesaler and controlled substances distributor/manufacturer
`
`with the Delaware Division of Professional Regulation; (3) intends to market, sell, or distribute
`
`Lupin’s ANDA Products to residents of this State; (4) makes its generic drug products available
`
`in this State; and (5) enjoys substantial income from sales of its generic pharmaceutical products
`
`in this State.
`
`
`
`On information and belief, Lupin Pharma has not contested jurisdiction in
`
`Delaware in one or more prior cases arising out of the filing of its ANDAs, and it has filed
`
`counterclaims in such cases. See, e.g., Boehringer Ingelheim Pharm. Inc. v. Lupin Ltd., C.A. No.
`
`18-1690-CFC (D. Del.); Alcon Research, Ltd. v. Lupin Ltd., C.A. No. 16-195-GMS-SRF
`
`(D. Del.); Boehringer Ingelheim Pharmaceuticals Inc. et al v. Lupin Limited et al, C.A. No. 19-
`
`01866-CFC (D. Del.).
`
`
`
`
`
`5
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 6 of 25 PageID #: 6
`
`
`
`BACKGROUND
`
`U.S. PATENT NO. 8,551,957
`
`
`
`On October 8, 2013, the USPTO duly and legally issued United States Patent No.
`
`8,551,957
`
`(the “’957 Patent”) entitled “Pharmaceutical Composition Comprising a
`
`Glucopyranosyl-Substituted Benzene Derivate” to inventors Klaus Dugi, Michael Mark, Leo
`
`Thomas and Frank Himmelsbach. A true and correct copy of the ’957 Patent is attached as
`
`Exhibit 1. The ’957 Patent is assigned to BII. BIC and BIPI are licensees of the ’957 Patent.
`
`U.S. PATENT NO. 9,155,705
`
`
`
`On October 13, 2015, the USPTO duly and legally issued United States Patent
`
`No. 9,155,705 (the “’705 Patent”) entitled “DPP-IV Inhibitor Combined with a Further
`
`Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use and Process for Their
`
`Preparation” to inventors Thomas Friedl, Michael Braun, Kenji Egusa, Hikaru Fujita, Megumi
`
`Maruyama, and Takaaki Nishioka. A true and correct copy of the ’705 Patent is attached as
`
`Exhibit 2. The ’705 Patent is assigned to BII. BIC and BIPI are licensees of the ’705 Patent.
`
`U.S. PATENT NO. 9,415,016
`
`
`
`On August 16, 2016, the PTO duly and legally issued United States Patent No.
`
`9,415,016 (the “’016 Patent”) entitled “DPP-IV inhibitor combined with a further antidiabetic
`
`agent, tablets comprising such formulations, their use and process for their preparation” to
`
`inventors Thomas Friedl, Michael Braun, Kenji Egusa, Hikaru Fujita, Megumi Maruyama, and
`
`Takaaki Nishioka. A true and correct copy of the ’016 Patent is attached as Exhibit 3. The ’016
`
`Patent is assigned to BII. BIC and BIPI are licensees of the ’016 Patent.
`
`U.S. PATENT NO. 9,949,998
`
`
`
`On April 24, 2018, the USPTO duly and legally issued United States Patent No.
`
`9,949,998 (the “’998 Patent”) entitled “Pharmaceutical Composition, Methods for Treating and
`
`6
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 7 of 25 PageID #: 7
`
`
`
`Uses Thereof” to inventors Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, and
`
`Hans-Juergen Woerle. A true and correct copy of the ’998 Patent is attached as Exhibit 4. The
`
`’998 Patent is assigned to BII. BIC and BIPI are licensees of the ’998 Patent.
`
`U.S. PATENT NO. 10,022,379
`
`
`
`On July 17, 2018, the PTO duly and legally issued United States Patent No.
`
`10,022,379 (the “’379 Patent”) entitled “DPP-IV inhibitor combined with a further antidiabetic
`
`agent, tablets comprising such formulations, their use and process for their preparation” to
`
`inventors Thomas Friedl, Michael Braun, Kenji Egusa, Hikaru Fujita, Megumi Maruyama, and
`
`Takaaki Nishioka. A true and correct copy of the ’379 Patent is attached as Exhibit 5. The ’379
`
`Patent is assigned to BII. BIC and BIPI are licensees of the ’379 Patent.
`
`U.S. PATENT NO. 10,258,637
`
`
`
`On April 16, 2019, the USPTO duly and legally issued United States Patent No.
`
`10,258,637 (the “’637 Patent”) entitled “Pharmaceutical Composition, Method for Treating and
`
`Uses Thereof” to inventors Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, and
`
`Hans-Juergen Woerle. A true and correct copy of the ’637 Patent is attached as Exhibit 6. The
`
`’637 Patent is assigned to BII. BIC and BIPI are licensees of the ’637 Patent.
`
`U.S. PATENT NO. 10,406,172
`
`
`
`On September 10, 2019, the USPTO duly and legally issued United States Patent
`
`No. 10,406,172 (the “’172 Patent”) entitled “Pharmaceutical Composition, Method for Treating
`
`and Uses Thereof” to inventors Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas,
`
`Uli Broedl, and Rolf Grempler. A true and correct copy of the ’172 Patent is attached as
`
`Exhibit 7. The ’172 Patent is assigned to BII. BIC and BIPI are licensees of the ’172 Patent.
`
`
`
`
`
`7
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 8 of 25 PageID #: 8
`
`
`
`TRIJARDY® XR
`
`
`
`BIPI is the holder of New Drug Application (“NDA”) No. 212614 for
`
`empagliflozin-linagliptin-metformin hydrochloride extended-release tablets, for oral use, in
`
`5 mg/2.5 mg/1000 mg, 10 mg/5 mg/1000 mg, 12.5 mg/2.5 mg/1000 mg, and 25 mg/5 mg/1000
`
`mg dosages, which is sold under the trade name TRIJARDY® XR.
`
`
`
`TRIJARDY® XR is listed in the FDA’s Approved Drug Products with
`
`Therapeutic Equivalence Evaluations database (“Orange Book”).
`
`
`
`Pursuant to 21 U.S.C. § 355(b)(1), and attendant FDA regulations, the ’957, ’705,
`
`’016, ’998, ’379, ’637, and ’172 Patents are listed in the Orange Book with respect to
`
`TRIJARDY® XR.
`
`
`
`The ’957, ’705, ’016, ’998, ’379, ’637, and ’172 Patents cover the pharmaceutical
`
`composition and use of TRIJARDY® XR.
`
`ACTS GIVING RISE TO THIS ACTION
`
`COUNT I — INFRINGEMENT OF THE ’957 PATENT
`
`Plaintiffs reallege paragraphs 1-32 as if fully set forth herein.
`
`On information and belief, Lupin submitted the Lupin ANDA to the FDA,
`
`
`
`
`
`pursuant to 21 U.S.C. § 355(j), seeking approval to market the Lupin ANDA Product.
`
`
`
`Lupin has represented that the Lupin ANDA refers to and relies upon the
`
`TRIJARDY® XR NDA and contains data that, according to Lupin, demonstrate the
`
`bioavailability or bioequivalence of the Lupin ANDA Products to TRIJARDY® XR.
`
`
`
`Plaintiffs received letters from Lupin on or about March 4, 2021 stating that
`
`Lupin had
`
`included certifications
`
`in
`
`the Lupin ANDA, pursuant
`
`to 21 U.S.C.
`
`§ 355(j)(2)(A)(vii)(IV), that, inter alia, certain claims of the ’957 Patent are either invalid or will
`
`not be infringed by the commercial manufacture, use, or sale of the Lupin ANDA Products (the
`
`8
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 9 of 25 PageID #: 9
`
`
`
`“Lupin Paragraph IV Certifications”). Lupin intends to engage in the commercial manufacture,
`
`use, offer for sale, and/or sale of the Lupin ANDA Products prior to the expiration of the ’957
`
`Patent.
`
`
`
`Lupin has infringed at least one claim of the ’957 Patent, pursuant to 35 U.S.C.
`
`§ 271(e)(2)(A), by submitting, or causing to be submitted the Lupin ANDA, by which Lupin
`
`seeks approval from the FDA to engage in the manufacture, use, offer to sell, sale, or importation
`
`of the Lupin ANDA Products prior to the expiration of the ’957 Patent.
`
`
`
`Lupin has declared its intent to manufacture, use, offer to sell, or sell in the United
`
`States or to import into the United States, the Lupin ANDA Products in the event that the FDA
`
`approves the Lupin ANDA. Accordingly, an actual and immediate controversy exists regarding
`
`Lupin’s infringement of the ’957 Patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`
`
`Lupin’s use, offer to sell, or sale of the Lupin ANDA Products in the United
`
`States during the term of the ’957 Patent would further infringe at least one claim of the ’957
`
`Patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`
`
`On information and belief, the Lupin ANDA Product, when offered for sale, sold,
`
`and/or when used as directed, would be used in a manner that would directly infringe at least one
`
`of the claims of the ’957 Patent either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, the use of the Lupin ANDA Product constitutes a
`
`material part of at least one of the claims of the ’957 Patent; Lupin knows that its ANDA Product
`
`is especially made or adapted for use in infringing at least one of the claims of the ’957 Patent,
`
`either literally or under the doctrine of equivalents; and its ANDA Product is not a staple article
`
`of commerce or commodity of commerce suitable for substantial noninfringing use.
`
`9
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 10 of 25 PageID #: 10
`
`
`
`
`
`On information and belief, the offering to sell or sale of the Lupin ANDA Product
`
`would contributorily infringe at least one of the claims of the ’957 Patent, either literally or under
`
`the doctrine of equivalents.
`
`
`
`On information and belief, Lupin had knowledge of the ’957 Patent and, by its
`
`promotional activities and package inserts for its ANDA Products, knows or should know that it
`
`will aid and abet another’s direct infringement of at least one of the claims of the ’957 Patent,
`
`either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, the offering to sell or sale of the Lupin ANDA Product
`
`by Lupin would actively induce infringement of at least one of the claims of the ’957 Patent,
`
`either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, Lupin does not deny that the Lupin ANDA Product
`
`will infringe the claims of the ’957 Patent and in the Lupin Paragraph IV Certification, Lupin did
`
`not deny that the Lupin ANDA Product subject to ANDA No. 215072 will infringe the claims of
`
`the ’957 Patent.
`
`
`
`Plaintiffs will be substantially and irreparably harmed if Lupin is not enjoined
`
`from infringing the ’957 Patent.
`
`
`
`This is an exceptional case within the meaning of 35 U.S.C. § 285, which
`
`warrants reimbursement of Boehringer’s reasonable attorney fees.
`
`COUNT II — INFRINGEMENT OF THE ’705 PATENT
`
`Plaintiffs reallege paragraphs 1-47 as if fully set forth herein.
`
`On information and belief, Lupin submitted the Lupin ANDA to the FDA,
`
`
`
`
`
`pursuant to 21 U.S.C. § 355(j), seeking approval to market the Lupin ANDA Product.
`
`10
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 11 of 25 PageID #: 11
`
`
`
`
`
`Lupin has represented that the Lupin ANDA refers to and relies upon the
`
`TRIJARDY® XR NDA and contains data that, according to Lupin, demonstrate the
`
`bioavailability or bioequivalence of the Lupin ANDA Products to TRIJARDY® XR.
`
`
`
`Plaintiffs received letters from Lupin on or about March 4, 2021 stating that
`
`Lupin had
`
`included certifications
`
`in
`
`the Lupin ANDA, pursuant
`
`to 21 U.S.C.
`
`§ 355(j)(2)(A)(vii)(IV), that, inter alia, certain claims of the ’705 Patent are either invalid or will
`
`not be infringed by the commercial manufacture, use, or sale of the Lupin ANDA Products (the
`
`“Lupin Paragraph IV Certifications”). Lupin intends to engage in the commercial manufacture,
`
`use, offer for sale, and/or sale of the Lupin ANDA Products prior to the expiration of the ’705
`
`Patent.
`
`
`
`Lupin has infringed at least one claim of the ’705 Patent, pursuant to 35 U.S.C.
`
`§ 271(e)(2)(A), by submitting, or causing to be submitted the Lupin ANDA, by which Lupin
`
`seeks approval from the FDA to engage in the manufacture, use, offer to sell, sale, or importation
`
`of the Lupin ANDA Products prior to the expiration of the ’705 Patent.
`
`
`
`Lupin has declared its intent to manufacture, use, offer to sell, or sell in the United
`
`States or to import into the United States, the Lupin ANDA Product in the event that the FDA
`
`approves the Lupin ANDA. Accordingly, an actual and immediate controversy exists regarding
`
`Lupin’s infringement of the ’705 Patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`
`
`Lupin’s use, offer to sell, or sale of the Lupin ANDA Products in the United
`
`States during the term of the ’705 Patent would further infringe at least one claim of the ’705
`
`Patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`11
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 12 of 25 PageID #: 12
`
`
`
`
`
`On information and belief, the Lupin ANDA Product, when offered for sale, sold,
`
`and/or when used as directed, would be used in a manner that would directly infringe at least one
`
`of the claims of the ’705 Patent either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, the use of the Lupin ANDA Product constitutes a
`
`material part of at least one of the claims of the ’705 Patent; Lupin knows that its ANDA Product
`
`is especially made or adapted for use in infringing at least one of the claims of the ’705 Patent,
`
`either literally or under the doctrine of equivalents; and its ANDA Product is not a staple article
`
`of commerce or commodity of commerce suitable for substantial noninfringing use.
`
`
`
`On information and belief, the offering to sell or sale of the Lupin ANDA Product
`
`would contributorily infringe at least one of the claims of the ’705 Patent, either literally or under
`
`the doctrine of equivalents.
`
`
`
`On information and belief, Lupin had knowledge of the ’705 Patent and, by its
`
`promotional activities and package inserts for its ANDA Products, knows or should know that it
`
`will aid and abet another’s direct infringement of at least one of the claims of the ’705 Patent,
`
`either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, the offering to sell or sale of the Lupin ANDA Product
`
`by Lupin would actively induce infringement of at least one of the claims of the ’705 Patent,
`
`either literally or under the doctrine of equivalents.
`
`
`
`Plaintiffs will be substantially and irreparably harmed if Lupin is not enjoined
`
`from infringing the ’705 Patent.
`
`
`
`This is an exceptional case within the meaning of 35 U.S.C. § 285, which
`
`warrants reimbursement of Boehringer’s reasonable attorney fees.
`
`
`
`
`
`12
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 13 of 25 PageID #: 13
`
`
`
`COUNT III — INFRINGEMENT OF THE ’016 PATENT
`
`Plaintiffs reallege paragraphs 1-61 as if fully set forth herein.
`
`On information and belief, Lupin submitted the Lupin ANDA to the FDA,
`
`
`
`
`
`pursuant to 21 U.S.C. § 355(j), seeking approval to market the Lupin ANDA Product.
`
`
`
`Lupin has represented that the Lupin ANDA refers to and relies upon the
`
`TRIJARDY® XR NDA and contains data that, according to Lupin, demonstrate the
`
`bioavailability or bioequivalence of the Lupin ANDA Products to TRIJARDY® XR.
`
`
`
`Plaintiffs received letters from Lupin on or about March 4, 2021 stating that
`
`Lupin had
`
`included certifications
`
`in
`
`the Lupin ANDA, pursuant
`
`to 21 U.S.C.
`
`§ 355(j)(2)(A)(vii)(IV), that, inter alia, certain claims of the ’016 Patent are either invalid or will
`
`not be infringed by the commercial manufacture, use, or sale of the Lupin ANDA Products (the
`
`“Lupin Paragraph IV Certifications”). Lupin intends to engage in the commercial manufacture,
`
`use, offer for sale, and/or sale of the Lupin ANDA Products prior to the expiration of the ’016
`
`Patent.
`
`
`
`Lupin has infringed at least one claim of the ’016 Patent, pursuant to 35 U.S.C.
`
`§ 271(e)(2)(A), by submitting, or causing to be submitted the Lupin ANDA, by which Lupin
`
`seeks approval from the FDA to engage in the manufacture, use, offer to sell, sale, or importation
`
`of the Lupin ANDA Products prior to the expiration of the ’016 Patent.
`
`
`
`Lupin has declared its intent to manufacture, use, offer to sell, or sell in the United
`
`States or to import into the United States, the Lupin ANDA Product in the event that the FDA
`
`approves the Lupin ANDA. Accordingly, an actual and immediate controversy exists regarding
`
`Lupin’s infringement of the ’016 Patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`13
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 14 of 25 PageID #: 14
`
`
`
`
`
`Lupin’s use, offer to sell, or sale of the Lupin ANDA Products in the United
`
`States during the term of the ’016 Patent would further infringe at least one claim of the ’016
`
`Patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`
`
`On information and belief, the Lupin ANDA Product, when offered for sale, sold,
`
`and/or when used as directed, would be used in a manner that would directly infringe at least one
`
`of the claims of the ’016 Patent either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, the use of the Lupin ANDA Product constitutes a
`
`material part of at least one of the claims of the ’016 Patent; Lupin knows that its ANDA Product
`
`is especially made or adapted for use in infringing at least one of the claims of the ’016 Patent,
`
`either literally or under the doctrine of equivalents; and its ANDA Product is not a staple article
`
`of commerce or commodity of commerce suitable for substantial noninfringing use.
`
`
`
`On information and belief, the offering to sell or sale of the Lupin ANDA Product
`
`would contributorily infringe at least one of the claims of the ’016 Patent, either literally or under
`
`the doctrine of equivalents.
`
`
`
`On information and belief, Lupin had knowledge of the ’016 Patent and, by its
`
`promotional activities and package inserts for its ANDA Products, knows or should know that it
`
`will aid and abet another’s direct infringement of at least one of the claims of the ’016 Patent,
`
`either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, the offering to sell or sale of the Lupin ANDA Product
`
`by Lupin would actively induce infringement of at least one of the claims of the ’016 Patent,
`
`either literally or under the doctrine of equivalents.
`
`
`
`Plaintiffs will be substantially and irreparably harmed if Lupin is not enjoined
`
`from infringing the ’016 Patent.
`
`14
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 15 of 25 PageID #: 15
`
`
`
`
`
`This is an exceptional case within the meaning of 35 U.S.C. § 285, which
`
`warrants reimbursement of Boehringer’s reasonable attorney fees.
`
`COUNT IV — INFRINGEMENT OF THE ’998 PATENT
`
`Plaintiffs reallege paragraphs 1-75 as if fully set forth herein.
`
`On information and belief, Lupin submitted the Lupin ANDA to the FDA,
`
`
`
`
`
`pursuant to 21 U.S.C. § 355(j), seeking approval to market the Lupin ANDA Product.
`
`
`
`Lupin has represented that the Lupin ANDA refers to and relies upon the
`
`TRIJARDY® XR NDA and contains data that, according to Lupin, demonstrate the
`
`bioavailability or bioequivalence of the Lupin ANDA Products to TRIJARDY® XR.
`
`
`
`Plaintiffs received letters from Lupin on or about March 4, 2021 stating that
`
`Lupin had
`
`included certifications
`
`in
`
`the Lupin ANDA, pursuant
`
`to 21 U.S.C.
`
`§ 355(j)(2)(A)(vii)(IV), that, inter alia, certain claims of the ’998 Patent are either invalid or will
`
`not be infringed by the commercial manufacture, use, or sale of the Lupin ANDA Products (the
`
`“Lupin Paragraph IV Certifications”). Lupin intends to engage in the commercial manufacture,
`
`use, offer for sale, and/or sale of the Lupin ANDA Products prior to the expiration of the ’998
`
`Patent.
`
`
`
`Lupin has infringed at least one claim of the ’998 Patent, pursuant to 35 U.S.C.
`
`§ 271(e)(2)(A), by submitting, or causing to be submitted the Lupin ANDA, by which Lupin
`
`seeks approval from the FDA to engage in the manufacture, use, offer to sell, sale, or importation
`
`of the Lupin ANDA Products prior to the expiration of the ’998 Patent.
`
`
`
`Lupin has declared its intent to manufacture, use, offer to sell, or sell in the United
`
`States or to import into the United States, the Lupin ANDA Product in the event that the FDA
`
`approves the Lupin ANDA. Accordingly, an actual and immediate controversy exists regarding
`
`Lupin’s infringement of the ’998 Patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`15
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 16 of 25 PageID #: 16
`
`
`
`
`
`Lupin’s use, offer to sell, or sale of the Lupin ANDA Products in the United
`
`States during the term of the ’998 Patent would further infringe at least one claim of the ’998
`
`Patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`
`
`On information and belief, the Lupin ANDA Product, when offered for sale, sold,
`
`and/or when used as directed, would be used in a manner that would directly infringe at least one
`
`of the claims of the ’998 Patent either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, the use of the Lupin ANDA Product constitutes a
`
`material part of at least one of the claims of the ’998 Patent; Lupin knows that its ANDA Product
`
`is especially made or adapted for use in infringing at least one of the claims of the ’998 Patent,
`
`either literally or under the doctrine of equivalents; and its ANDA Product is not a staple article
`
`of commerce or commodity of commerce suitable for substantial noninfringing use.
`
`
`
`On information and belief, the offering to sell or sale of the Lupin ANDA Product
`
`would contributorily infringe at least one of the claims of the ’998 Patent, either literally or under
`
`the doctrine of equivalents.
`
`
`
`On information and belief, Lupin had knowledge of the ’998 Patent and, by its
`
`promotional activities and package inserts for its ANDA Products, knows or should know that it
`
`will aid and abet another’s direct infringement of at least one of the claims of the ’998 Patent,
`
`either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, the offering to sell or sale of the Lupin ANDA Product
`
`by Lupin would actively induce infringement of at least one of the claims of the ’998 Patent,
`
`either literally or under the doctrine of equivalents.
`
`
`
`On information and belief, Lupin does not deny that the Lupin ANDA Product
`
`will infringe the claims of the ’998 Patent and in the Lupin Paragraph IV Certification, Lupin did
`
`16
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 17 of 25 PageID #: 17
`
`
`
`not deny that the Lupin ANDA Product subject to ANDA No. 215072 will infringe the claims of
`
`the ’998 Patent.
`
`
`
`Plaintiffs will be substantially and irreparably harmed if Lupin is not enjoined
`
`from infringing the ’998 Patent.
`
`
`
`This is an exceptional case within the meaning of 35 U.S.C. § 285, which
`
`warrants reimbursement of Boehringer’s reasonable attorney fees.
`
`COUNT V — INFRINGEMENT OF THE ’379 PATENT
`
`Plaintiffs reallege paragraphs 1-90 as if fully set forth herein.
`
`On information and belief, Lupin submitted the Lupin ANDA to the FDA,
`
`
`
`
`
`pursuant to 21 U.S.C. § 355(j), seeking approval to market the Lupin ANDA Product.
`
`
`
`Lupin has represented that the Lupin ANDA refers to and relies upon the
`
`TRIJARDY® XR NDA and contains data that, according to Lupin, demonstrate the
`
`bioavailability or bioequivalence of the Lupin ANDA Products to TRIJARDY® XR.
`
`
`
`Plaintiffs received letters from Lupin on or about March 4, 2021 stating that
`
`Lupin had
`
`included certifications
`
`in
`
`the Lupin ANDA, pursuant
`
`to 21 U.S.C.
`
`§ 355(j)(2)(A)(vii)(IV), that, inter alia, certain claims of the ’379 Patent are either invalid or will
`
`not be infringed by the commercial manufacture, use, or sale of the Lupin ANDA Products (the
`
`“Lupin Paragraph IV Certifications”). Lupin intends to engage in the commercial manufacture,
`
`use, offer for sale, and/or sale of the Lupin ANDA Products prior to the expiration of the ’379
`
`Patent.
`
`
`
`Lupin has infringed at least one claim of the ’379 Patent, pursuant to 35 U.S.C.
`
`§ 271(e)(2)(A), by submitting, or causing to be submitted the Lupin ANDA, by which Lupin
`
`seeks approval from the FDA to engage in the manufacture, use, offer to sell, sale, or importation
`
`of the Lupin ANDA Products prior to the expiration of the ’379 Patent.
`
`17
`
`

`

`Case 1:21-cv-00530-UNA Document 1 Filed 04/13/21 Page 18 of 25 PageID #: 18
`
`
`
`
`
`Lupin has declared its intent to manufacture, use, offer to sell, or sell in the United
`
`States or to import into the United States, the Lupin ANDA Product in the event that the FDA
`
`approves the Lupin ANDA. Accordingly, an actual and immediate controversy exists regarding
`
`Lupin’s infringement of the ’379 Patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`
`
`Lupin’s use, offer to sell, or sale of the Lupin ANDA Products in the United
`
`States during the term of the ’379 Patent would further infringe at least one claim of the ’379
`
`Patent under 35 U.S.C. §§ 271 (a), (b), and/or (c).
`
`
`
`On information and belief, the Lupin ANDA Product, when offered for sale, s

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket